Characteristic | Afatinib-naïve |
---|---|
Patients, number | 51 |
Gender, number (%) | |
Male | 48 (94%) |
Female | 3 (6%) |
Age, median (range) (years) | 59.2 (34.4–74.0) |
Cancer type, number (%) | |
Oral cavity | 36 (70%) |
Oropharynx | 8 (16%) |
p16 status: ( +) / (-) / NA | 1 / 5 / 2 |
Hypopharynx | 7 (14%) |
Habits, number (%) | |
Alcohol drinking | 35 (69%) |
Betel nut chewing | 36 (71%) |
Cigarette smoking | 44 (86%) |
Definitive treatment | |
Surgery–CCRT | 35 (69%) |
Definitive CCRT | 11 (21%) |
Surgery alone | 5 (10%) |
Time from definitive therapy to recurrence/metastases (%) | |
0–90 days | 10 (20%) |
91–180 days | 16 (31%) |
≥ 181 days | 25 (49%) |
Cetuximab, number (%) | |
Naïve | 44 (86%) |
Induction | 1 (2%) |
Bio-RT | 1 (2%) |
For recurrent/metastatic disease | 5 (10%) |
Pembrolizumab, dose/cycle | |
200 mg fixed dose | 27 (52%) |
2 mg/kg | 25 (48%) |
Pembrolizumab, cycles | |
1–3 cycles | 13 (25%) |
4 cycles | 34 (67%) |
5–7 cycles | 4 (8%) |